Premium
Can a cyclo‐oxygenase type‐2 selective tocolytic agent avoid the fetal side effects of indomethacin?
Author(s) -
Locatelli Anna,
Vergani Patrizia,
Bellini Primula,
Strobelt Nicola,
Ghidini Alessandro
Publication year - 2001
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.2001.00071.x
Subject(s) - nimesulide , oligohydramnios , medicine , discontinuation , tocolytic , tocolytic agent , fetus , pregnancy , anesthesia , ritodrine , obstetrics , side effect (computer science) , preterm labor , surgery , pharmacology , gestation , biology , genetics , computer science , programming language
We evaluated the efficacy and safety of nimesulide (100 mg orally twice daily for > 48 hours) in a pilot series of five women (two with twin pregnancies) at 24 +6 weeks ( range 21 +3 –27 +2 ) in preterm labour which was unresponsive to intravenous ritodrine. Nimesulide therapy was continued for eight days (5–16) and was associated with a prolongation of pregnancy of 27 days (6–69). Oligohydramnios occurred in all seven fetuses after three to nine days of therapy, and in the five pregnancies that continued after discontinuation of nimesulide, it resolved within four days (2–7). None of the babies manifested permanent renal damage.